Fineline Cube

Follow:
14436 Articles
Novartis' Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment
CompanyDrug

Novartis’ Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment

EMA's CHMP Issues Negative Opinion on Lilly's Kisunla for Alzheimer's
CompanyDrug

EMA’s CHMP Issues Negative Opinion on Lilly’s Kisunla for Alzheimer’s

China's IAC Drafts Commercial Health Insurance Drug List A-Series to Bridge NRDL Coverage Gaps
Policy / Regulatory

China’s IAC Drafts Commercial Health Insurance Drug List A-Series to Bridge NRDL Coverage Gaps

China Scraps Outpatient Prepayment in Public Hospitals by 2025: Healthcare Reform Shifts Financial Burden
Policy / Regulatory

China Scraps Outpatient Prepayment in Public Hospitals by 2025: Healthcare Reform Shifts Financial Burden

uBriGene Appoints Dr. Joy Zhou to Lead Cell Therapy Development
Company

uBriGene Appoints Dr. Joy Zhou to Lead Cell Therapy Development

BMS's Opdivo/Yervoy Combo Approved by NMPA for First-Line HCC Treatment
CompanyDrug

BMS’s Opdivo/Yervoy Combo Approved by NMPA for First-Line HCC Treatment

Roche's Ocrevus Approved by China's NMPA for Multiple Sclerosis Treatment
CompanyDrug

Roche’s Ocrevus Approved by China’s NMPA for Multiple Sclerosis Treatment

Shanghai Bio-heart Launches SAKURA-SCB Study for Drug-Coated Balloon in Japan
CompanyMedical Device

Shanghai Bio-heart Launches SAKURA-SCB Study for Drug-Coated Balloon in Japan

AstraZeneca's Imfinzi Approved by FDA for Bladder Cancer Treatment
CompanyDrug

AstraZeneca’s Imfinzi Approved by FDA for Bladder Cancer Treatment

MicroPort Endovascular Reports 1.61% Revenue Growth in 2024 with Strong Profit Increase
Company

MicroPort Endovascular Reports 1.61% Revenue Growth in 2024 with Strong Profit Increase

Luye Pharma Group Reports 2024 Revenue Dip Despite Growth in Product Sales
Company

Luye Pharma Group Reports 2024 Revenue Dip Despite Growth in Product Sales

Hengrui Pharmaceuticals Reports 22.63% Revenue Growth in 2024 with Strong Innovative Drug Sales
Company

Hengrui Pharmaceuticals Reports 22.63% Revenue Growth in 2024 with Strong Innovative Drug Sales